Track protection status across key markets to assess launch feasibility.
It is formulated by 5 pharmaceutical companies such as FRESENIUS KABI USA, AMPHASTAR PHARMS INC, XERIS and others. It is marketed under 8 brand names, including GLUCAGON, BAQSIMI, GVOKE HYPOPEN and others. Available in 6 different strengths, such as EQ 1MG BASE/VIAL, 3MG, 0.5MG/0.1ML (0.5MG/0.1ML) and others, and administered through 6 routes including POWDER;INTRAMUSCULAR, INTRAVENOUS, POWDER;NASAL, SOLUTION;SUBCUTANEOUS and others.
API availability: Loading API feasibility...
Licensing: 5 potential partnersUS Launch window: Loading launch window...
Stay ahead with worldwide patent expiry and latest updates.
FDA approval history for this ingredient
Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.
Key expiration dates for US patents covering this ingredient
Stay ahead with worldwide patent expiry insights, market data, and research updates.
Latest drug strengths approved by FDA
Strength | Route of Administration | Companies | Latest Approval Date |
---|
Patents approved by the FDA for the ingredient
|
Patent Number | Publication Date | Legal Status | Patent Expiry Date | |
---|---|---|---|---|---|
{"application_id":"80424","ingredient":"DASIGLUCAGON HYDROCHLORIDE","trade_name":"ZEGALOGUE","family_id":"dfdf4841554944e7b895","publication_number":"US11795204B2","cleaned_patent_number":"11795204","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-01-06","publication_date":"2023-10-24","legal_status":"Granted"} | US11795204B2 | 24 Oct, 2023 | Granted | 06 Jan, 2034 | |
{"application_id":"80397","ingredient":"DASIGLUCAGON HYDROCHLORIDE","trade_name":"ZEGALOGUE","family_id":"f5ff21de07a540a4a2a9","publication_number":"US10442847B2","cleaned_patent_number":"10442847","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-02-03","publication_date":"2019-10-15","legal_status":"Granted"} | US10442847B2 Molecular Formulation | 15 Oct, 2019 | Granted | 03 Feb, 2035 | |
{"application_id":"68888","ingredient":"GLUCAGON","trade_name":"BAQSIMI","family_id":"e11d7cb6d12147468d9f","publication_number":"US10213487B2","cleaned_patent_number":"10213487","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-02-16","publication_date":"2019-02-26","legal_status":"Granted"} | US10213487B2 Formulation | 26 Feb, 2019 | Granted | 16 Feb, 2036 | |
{"application_id":"77926","ingredient":"GLUCAGON","trade_name":"GVOKE HYPOPEN","family_id":"cff0d01bf217446db4e2","publication_number":"US11590205B2","cleaned_patent_number":"11590205","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-04-22","publication_date":"2023-02-28","legal_status":"Granted"} | US11590205B2 Formulation | 28 Feb, 2023 | Granted | 22 Apr, 2036 | |
{"application_id":"77912","ingredient":"GLUCAGON","trade_name":"GVOKE HYPOPEN","family_id":"fed3a019d2304cbfacdf","publication_number":"US9649364B2","cleaned_patent_number":"9649364","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-04-22","publication_date":"2017-05-16","legal_status":"Granted"} | US9649364B2 Formulation | 16 May, 2017 | Granted | 22 Apr, 2036 | |
{"application_id":"68946","ingredient":"GLUCAGON","trade_name":"BAQSIMI","family_id":"","publication_number":"US10765602B1","cleaned_patent_number":"10765602","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-09-23","publication_date":"2020-09-08","legal_status":"Granted"} | US10765602B2 Formulation | 08 Sep, 2020 | Granted | 23 Sep, 2039 |
Latest clinical trials and research studies for this ingredient
NCT ID | Title | Status | Phase | Conditions | Start Date | Completion Date |
---|
Manufacturing Locations
Unlock access to all suppliers of Glucagon
Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.